Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamou
Keywords: ALIMTA; Low-grade toxicities; LY231514; NS-NSCLC; Post-induction maintenance therapy;